What is the recommended treatment for community-acquired pneumonia in an otherwise healthy adult?

Treatment of Community-Acquired Pneumonia in Healthy Adults

For an otherwise healthy adult with community-acquired pneumonia managed as an outpatient, treat with amoxicillin 1g three times daily as first-line monotherapy, or alternatively use a macrolide (azithromycin or clarithromycin) or doxycycline. 1

Outpatient Treatment Algorithm

First-Line Options for Previously Healthy Adults:

• Amoxicillin 1g three times daily (preferred for typical bacterial coverage, especially S. pneumoniae) 1
• Macrolide monotherapy: Azithromycin 500mg daily or clarithromycin 500mg twice daily 2
• Doxycycline 100mg twice daily 2

When to Use Alternative Regimens:

If the patient has comorbidities (chronic heart/lung/liver/renal disease, diabetes, alcoholism, immunosuppression) or recent antibiotic use within 3 months, escalate to:

• Respiratory fluoroquinolone (levofloxacin 750mg daily or moxifloxacin 400mg daily) 2, 1
• OR High-dose amoxicillin-clavulanate (2g twice daily) plus a macrolide 2

Critical caveat: The 2019 ATS/IDSA guidelines introduced beta-lactam monotherapy for uncomplicated outpatients, representing a shift from older guidelines that universally recommended atypical coverage 1. This reflects recognition that most healthy adults have pneumococcal disease responsive to beta-lactams.

Hospitalized Non-Severe CAP

For patients requiring hospitalization but not ICU admission, use combination therapy with a beta-lactam plus macrolide OR respiratory fluoroquinolone monotherapy. 2, 1

Preferred Regimens:

• Ceftriaxone 1-2g daily OR cefotaxime 1-2g every 8 hours PLUS azithromycin 500mg daily 1
• OR Ampicillin-sulbactam 1.5-3g every 6 hours PLUS macrolide 1
• OR Respiratory fluoroquinolone monotherapy (levofloxacin 750mg daily or moxifloxacin 400mg daily) 2, 1

Both approaches have equivalent efficacy based on multiple RCTs, though combination therapy may reduce mortality compared to beta-lactam monotherapy 1. Most patients can receive oral antibiotics if able to tolerate them 3.

Severe CAP Requiring ICU Admission

Patients with severe pneumonia requiring ICU care must receive immediate IV combination therapy with a beta-lactam PLUS either a macrolide or respiratory fluoroquinolone. 2

Standard Severe CAP Regimen:

• Ceftriaxone 1-2g daily OR cefotaxime 1-2g every 8 hours OR ampicillin-sulbactam 1.5-3g every 6 hours
• PLUS azithromycin 500mg daily OR levofloxacin 750mg daily 2

Special Considerations for Severe CAP:

If risk factors for Pseudomonas aeruginosa (structural lung disease, recent hospitalization, recent broad-spectrum antibiotics):

• Use antipseudomonal beta-lactam (piperacillin-tazobactam, cefepime, imipenem, or meropenem)
• PLUS ciprofloxacin or levofloxacin 750mg
• OR PLUS aminoglycoside and azithromycin 2

If risk factors for MRSA (recent influenza, IV drug use, known colonization):

• Add vancomycin or linezolid to the above regimen 2

Duration of Therapy

Treat for minimum 5 days, ensuring patient is afebrile for 48-72 hours and clinically stable before stopping antibiotics. 2

The 2019 guidelines support shorter courses (minimum 5 days) rather than the traditional 7-10 days, provided clinical stability is achieved 1. The most recent 2025 update suggests even 3-day courses may be adequate for non-severe CAP in patients achieving clinical stability by day 3 4, 5, 6.

Extend duration to 10-14 days for Legionella, Staphylococcus aureus, or gram-negative enteric bacteria 3.

Switching from IV to Oral Therapy

Switch to oral antibiotics when the patient is hemodynamically stable, clinically improving, afebrile, and able to ingest medications—typically within 48-72 hours. 2

Patients can be discharged immediately after switching to oral therapy; continued inpatient observation is unnecessary 2.

Key Pitfalls to Avoid

1. Do not use macrolide monotherapy for hospitalized patients—resistance rates make this inadequate 2, 3
2. Administer first antibiotic dose in the emergency department—delays worsen outcomes 2
3. Do not routinely repeat chest X-rays in patients with satisfactory clinical recovery before discharge 3
4. Arrange 6-week follow-up for all patients, with repeat imaging for smokers >50 years or those with persistent symptoms 3
5. Consider drug-resistant pathogens in patients with recent antibiotic exposure or healthcare contact 2, 1

The evidence strongly supports early, appropriate empirical therapy tailored to severity and risk factors, with de-escalation based on clinical response rather than prolonged courses.